Document is current
Any future updates will be listed below
-
Authors
Yabe, Mutsumi
Furukawa, Shoko
Takeyama, Masahiro https://orcid.org/0000-0002-9348-9815
Sasai, Kana
Shimonishi, Naruto
Nakajima, Yuto
Ogiwara, Kenichi
Nogami, Keiji
-
Funding
Funding for this research was provided by:
Grant-in-Aid for Scientific Research (21K07804)
- License Information
-
More Information
Article History
Received: 20 August 2025
Revised: 4 November 2025
Accepted: 4 November 2025
First Online: 11 November 2025
Declarations
:
: M.Y. and K.S. declare no conflicts of interest. S.F. has received personal fees from Takeda Pharmaceutical Co., CSL Behring, Chugai Pharmaceutical Co., Ltd., and Sanofi S.A. M.T. has received honoraria from CSL Behring, Sanofi K.K., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co., Ltd., Fujimoto Pharmaceutical Corporation, and Bayer Yakuhin Ltd.; research funding from Chugai Pharmaceutical Co., Ltd. and Japan Blood Products Organization; and has participated in advisory boards for Chugai Pharmaceutical Co., Ltd. and Sanofi K.K. N.S. teaches a course supported by CSL Behring. Y.N. has received personal fees from Chugai Pharmaceutical Co., Ltd., and grants from Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., and KM Biologics Co. K.O. has received personal fees from Takeda Pharmaceutical Co., Ltd., Chugai Pharmaceutical Co., Ltd., Sanofi S.A., and CSL Behring. K.N. has received personal fees, grants, and non-financial support from Chugai Pharmaceutical Co., Ltd.; personal fees from F. Hoffmann-La Roche Ltd.; personal fees and grants from SEKISUI MEDICAL, Sysmex Co., Takeda Pharmaceutical Co., Ltd., CSL Behring Co., Sanofi S.A., Bayer AG, KM Biologics Co., Novo Nordisk A/S, and Fujimoto Seiyaku; is a member of the IJH Editorial Board and holds patents related to emicizumab.
